215 related articles for article (PubMed ID: 35991604)
21. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
22. Biodistribution, pharmacokinetics, dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Evaluation of
Bendre S; Zhang Z; Colpo N; Zeisler J; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110717
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [
Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S
Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677
[TBL] [Abstract][Full Text] [Related]
25. SPECT Imaging with Tc-99m-Labeled HYNIC-FAPI-04 to Extend the Differential Time Window in Evaluating Tumor Fibrosis.
Luo X; Zhang Z; Cheng C; Wang T; Fang D; Zuo C; Yuan G; Li R; Li X
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986521
[TBL] [Abstract][Full Text] [Related]
26. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
27. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
Lindner T; Loktev A; Altmann A; Giesel F; Kratochwil C; Debus J; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2018 Sep; 59(9):1415-1422. PubMed ID: 29626119
[TBL] [Abstract][Full Text] [Related]
28. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
29. Clinical translational evaluation of Al
Wang S; Zhou X; Xu X; Ding J; Liu S; Hou X; Li N; Zhu H; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4259-4271. PubMed ID: 34165601
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Preliminary Study of
Ma M; Yang G; Zhao M; Liu Y; Ge X; Jia B; Gao S
Mol Pharm; 2024 Feb; 21(2):735-744. PubMed ID: 38193393
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation and pilot clinical study of [
Hu K; Li J; Wang L; Huang Y; Li L; Ye S; Han Y; Huang S; Wu H; Su J; Tang G
Acta Pharm Sin B; 2022 Feb; 12(2):867-875. PubMed ID: 35256951
[TBL] [Abstract][Full Text] [Related]
32. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
33. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [
Backhaus P; Gierse F; Burg MC; Büther F; Asmus I; Dorten P; Cufe J; Roll W; Neri D; Cazzamalli S; Millul J; Mock J; Galbiati A; Zana A; Schäfers KP; Hermann S; Weckesser M; Tio J; Wagner S; Breyholz HJ; Schäfers M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1822-1832. PubMed ID: 34957527
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and Preclinical Evaluation of Novel
Bendre S; Kuo HT; Merkens H; Zhang Z; Wong AAWL; Bénard F; Lin KS
Pharmaceuticals (Basel); 2023 May; 16(6):. PubMed ID: 37375746
[TBL] [Abstract][Full Text] [Related]
35. 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.
Ding J; Xu M; Chen J; Zhang P; Huo L; Kong Z; Liu Z
Mol Pharm; 2022 Sep; 19(9):3429-3438. PubMed ID: 35976352
[TBL] [Abstract][Full Text] [Related]
36. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
37. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
38. Microfluidic-based production of [
Mallapura H; Ovdiichuk O; Jussing E; Thuy TA; Piatkowski C; Tanguy L; Collet-Defossez C; Långström B; Halldin C; Nag S
EJNMMI Radiopharm Chem; 2023 Dec; 8(1):42. PubMed ID: 38091157
[TBL] [Abstract][Full Text] [Related]
39.
Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
[TBL] [Abstract][Full Text] [Related]
40. Head-to-head Intra-individual Comparison of [
Novruzov E; Dendl K; Ndlovu H; Choyke PL; Dabir M; Beu M; Novruzov F; Mehdi E; Guliyev F; Koerber SA; Lawal I; Niegisch G; Debus J; Haberkorn U; Sathekge M; Giesel FL
Mol Imaging Biol; 2022 Aug; 24(4):651-658. PubMed ID: 35349039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
